immu claim to fame was picking up a deal with a china cos everest[[ $65 million payment ] subject to fda approval of their tnbc treatment drug trodelvy-fda approved april this year.in just a few short months immu had net sales of about $20 million with trodelvy.immu clearly did a stellar job for their shareholders fetching $20 bill as trodelvy appears to be a one trick pony drug albeit with plenty of side effects.re cydy i recall we signed a deal with a china cos longen this past february exploring opportunities for covid and cancer license deals for our minimal sae leronlimab..why have not cydy made progress in asia?imo

https://www.webmd.com/drugs/2/drug-179218/tro...ideeffects